{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"9.3","value":"3.0"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"5.6","value":"2.6"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG002","lowerLimit":"1.4","upperLimit":"NA","value":"1.9"},{"groupId":"OG003","lowerLimit":"0.5","upperLimit":"4.9","value":"1.8"},{"groupId":"OG004","lowerLimit":"0.5","upperLimit":"8.5","value":"3.4"},{"groupId":"OG005","lowerLimit":"1.2","upperLimit":"7.4","value":"2.5"},{"groupId":"OG006","lowerLimit":"3.2","upperLimit":"5.7","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"65"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of the first administration of study drug until the date of first documentation of progressive disease (PD) per RECIST 1.1 or RANO (for HGG) or death (whichever occurs first).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Ewing sarcoma received lenvatinib 14 mg/m\\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.","id":"OG000","title":"Ewing Sarcoma"},{"description":"Participants with rhabdomyosarcoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG001","title":"Rhabdomyosarcoma"},{"description":"Participants with high grade glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG002","title":"High Grade Glioma"},{"description":"Participants with diffuse midline glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG003","title":"Diffuse Midline Glioma"},{"description":"Participants with medulloblastoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG004","title":"Medulloblastoma"},{"description":"Participants with ependymoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG005","title":"Ependymoma"},{"description":"Participants with other solid tumors received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG006","title":"Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma"}],"paramType":"MEDIAN","populationDescription":"All participants who had measurable disease present at baseline and at least one efficacy assessment, unless they discontinued prior to the first efficacy assessment due to progressive disease.","reportingStatus":"POSTED","timeFrame":"Up to approximately 21 months","title":"Progression Free Survival (PFS) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}